CB2 Agonist and Steroid Compositions for Cytokine Storm Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COVID-19 and other pathogen-induced cytokine storm syndrome and septic shock often lead to excessive immune suppression, increasing mortality in non-critical patients and potentially elevating viral loads, necessitating a composition that effectively mitigates inflammatory complications without weakening the immune system.
Innovation Solution
A combination of selective CB2 receptor agonists such as osteogenic growth peptide (OGP), olorinab, β-caryophyllene, and lenabasum with steroids like dehydroepiandrosterone (DHEA), DHEA-sulfate, and pregnenolone, which are administered to reduce inflammatory responses and prevent disease deterioration without compromising the immune system's ability to fight pathogens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If systemic corticosteroids such as dexamethasone are administered to COVID-19 patients, then inflammatory responses are suppressed, but immune system function is severely suppressed and viral load may increase
Solution Approach 1:
The patent segments the immune system into two functional components: the humoral/adaptive immune system (which fights pathogens) and the innate immune system (which produces cytokines). By selectively targeting CB2 receptors on innate immune cells, the treatment suppresses inflammatory cytokine production while preserving adaptive immune function, thus resolving the contradiction between reducing inflammation and maintaining immune defense.
Solution Approach 2:
The patent introduces CB2 receptor agonists as an intermediary substance that selectively modulates innate immune cell activity. These agonists act as mediators to suppress excessive cytokine production without directly affecting adaptive immune responses, thereby reducing inflammation while preserving the immune system's ability to fight pathogens.
2Ease of operation
If dexamethasone is used in non-critical patients without oxygen supplementation, then treatment is simplified, but mortality significantly increases
Solution Approach 1:
The patent applies local quality by creating different treatment regimens for different patient groups based on disease severity. Non-critical patients receive CB2 agonist monotherapy that suppresses inflammation without immunosuppression, while critical patients receive combination therapy with corticosteroids. This localized treatment approach ensures safety and effectiveness across different patient populations.
3Reliability
If corticosteroids are administered early in infection, then inflammatory complications may be prevented, but immune suppression occurs increasing vulnerability to pathogen
Solution Approach 1:
The patent extracts and targets specifically the harmful inflammatory cytokine production pathway through CB2 receptor activation, while leaving the protective adaptive immune response intact. This selective extraction of inflammatory suppression capability allows early treatment to prevent cytokine storm without causing general immune suppression that would increase viral load.
Data Source
AI summary
Pharmaceutical compositions are provided, comprising at least one selective CB2 receptor agonist and at least one steroid. The provided compositions are effective in treating inflammation and/or pathogen related inflammation and associated complications thereof. Also provided are methods for treating a subject infected with a pathogen as well as inflammation, using said compositions.